Table Filtering
Other Information
Release Statistics Download
GlyCosmos Glycolipids

Glycolipid entries from the LIPID MAPS Structure Database (LMSD).

Source Last Updated
LIPID MAPS Proteome Database (LMSD) June 16, 2024
Displaying entries 5026 - 5050 of 6046 in total
Sub Class LM ID Name LipidBank ID KEGG ID PubChem CID ChEBI ID Exact Mass Formula ▲
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505AM08
  • Fucalpha1-2Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
  • type II H antigen(d18:1/26:1(17Z))
44261075 1876.080902 C90H161N3O37
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505AS08
  • Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
  • Lex-7(d18:1/26:1(17Z))
44261123 1876.080902 C90H161N3O37
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505AV08
  • Galbeta1-4GlcNAcbeta1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
44261147 1876.080902 C90H161N3O37
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505CI08
  • Galbeta1-3(Fucalpha1-4)GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
44261459 1876.080902 C90H161N3O37
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505CK08
  • Galbeta1-3GlcNAcbeta1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
44261475 1876.080902 C90H161N3O37
Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506BJ08
  • Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galalpha1-3(GalNAcbeta1-4)Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
44261707 1876.080902 C90H161N3O37
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AG08
  • Galbeta1-3(Galbeta1-4GlcNAcbeta1-6)GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
44260219 1892.075817 C90H161N3O38
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505BL08
  • Galalpha1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/26:1(17Z))
44261275 1892.075817 C90H161N3O38
Gangliosides LMSP0601CB06
  • KDNalpha2-3Galbeta1-3GalNAcbeta1-4(NeuAcalpha2-3)Galbeta1-4Glcbeta-Cer(d18:1/26:0)
  • Neu5Ac)GD1a(d18:1/26:0)
44262393 1908.070732 C90H161N3O39
Gangliosides LMSP0601CC06
  • KDN)GD1a(d18:1/26:0)
  • NeuAcalpha2-3Galbeta1-3GalNAcbeta1-4(KDNalpha2-3)Galbeta1-4Glcbeta-Cer(d18:1/26:0)
44262401 1908.070732 C90H161N3O39
Gangliosides LMSP0601CD06
  • (KDN,Neu5Ac)GD1a 2(d18:1/26:0)
  • KDNalpha2-3Galbeta1-3(NeuAcalpha2-6)GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/26:0)
44262409 1908.070732 C90H161N3O39
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504AT03
  • Fucalpha1-2Galbeta1-4GlcNAcbeta1-3Galbeta1-3(Fucalpha1-4)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
44260766 1940.060562 C90H161N3O41
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504AW03
  • Fucalpha1-2Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
44260790 1940.060562 C90H161N3O41
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504BC03
  • Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-3(Fucalpha1-4)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
44260838 1940.060562 C90H161N3O41
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504BT03
  • Galbeta1-3(Fucalpha1-4)GlcNAcbeta1-3Galbeta1-3(Fucalpha1-4)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
44260958 1940.060562 C90H161N3O41
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505AI03
  • Fucalpha1-2Galbeta1-3GalNAcalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
  • type III H antigen(d18:1/20:0)
44261038 1940.060562 C90H161N3O41
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505AU03
  • Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
  • dimeric Lex(d18:1/20:0)
44261134 1940.060562 C90H161N3O41
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505AZ03
  • Fucalpha1-2Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
  • Ley-8(d18:1/20:0)
44261174 1940.060562 C90H161N3O41
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505CJ03
  • Galbeta1-3(Fucalpha1-4)GlcNAcbeta1-3Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
  • Lea -X(d18:1/20:0)
44261462 1940.060562 C90H161N3O41
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AH03
  • Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-6(Galbeta1-3)GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0)
  • globo-Lex-9(d18:1/20:0)
44260222 1956.055477 C90H161N3O42
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505AO03
  • Galalpha1-3(Fucalpha1-2)Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
  • type II B antigen(d18:1/20:0)
44261086 1956.055477 C90H161N3O42
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AY07
  • Galalpha1-3Galalpha1-3Galalpha1-3Galalpha1-3Galalpha1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:1(15Z))
44260362 1944.044244 C90H161NO43
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AX04
  • GalNAcbeta1-3Galalpha1-3Galalpha1-3Galalpha1-3Galalpha1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/22:0)
44260351 1959.055143 C90H162N2O43
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AT05
  • Branched Forssman(d18:1/24:0)
  • GalNAcalpha1-3GalNAcbeta1-3(Galbeta1-3GalNAcbeta1-4)Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44260320 1907.086716 C90H162N4O38
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504AO05
  • GalNAcalpha1-3Galbeta1-3GlcNAcbeta1-3Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44260728 1907.086716 C90H162N4O38

About Release Notes Help Feedback

Click here to visit the beta site.


International Collaboration

GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.

Acknowledgements

Supported by JST NBDC Grant Number JPMJND2204

Partly supported by NIH Common Fund Grant #1U01GM125267-01


Logo License Policies Site Map

Contact: support@glycosmos.org

This work is licensed under Creative Commons Attribution 4.0 International


GlyCosmos Portal v4.0.0

Last updated: August 19, 2024